8:00 a.m. to 8:30 a.m. -
Registration
8:30 a.m. to 3:45 p.m. -
Program
11:40 a.m. to 1:15 p.m. -
Lunch
Today’s biotech market is experiencing a slow but steady rebound.
But, in today’s market success doesn’t come easy. Excelling in a new financial and regulatory environment demands not only new approaches to raising and sustaining a cash flow and a strong IP and regulatory strategy, but also new models for building multinational collaborations. Bay Area life sciences companies are surviving in this difficult and evolving market and maintain the lead in terms of venture capital funding, cross-national collaborations and innovative product pipelines.
You are invited to join Foley & Lardner LLP, BayBIO, and Ernst & Young for Winning Strategies: How to Create, Grow, and Sustain a Successful Life Sciences Company. During this half-day conference, financial advisors, industry leaders, and legal counsel will provide insight on critical business, regulatory and legal issues during the following interactive panels:
Cross-Border R&D in China - Understanding the Regulatory Challenges
Keynote address by James Sabry, M.D., Ph.D and Vice President at Genentech Partnering
With closing remarks by Gail Maderis, President & CEO of BayBio.
Our Supporting Contributors Include:
For additional information, please contact Delia Dai at ddai@foley.com.
The global push to reduce the costs of both R&D and clinical trials, coupled with the large Chinese population and relative ease of enrolling clinical trial participants in China, is causing many U.S. pharmaceutical and biotech companies to consider doing R&D work in China even for drugs destined for sale outside of China. Awareness of differences in regulatory and business practices between China and the U. S. can make the difference between a successful result and failure for these efforts.
Moderated by:
Paul A. Stewart, Partner, Foley & Lardner LLP
Speakers:
David Rosen, Partner, Foley & Lardner LLP
Sofie Qiao, Ph.D, President, CEO and Co-Founder, LINQ Pharmaceuticals
Jimmy Z. Zhang, Ph.D., M.B.A, Vice President, Synergenics, LLC
The value of an innovative company’s intellectual property and how best to protect it globally is multifaceted. In today’s environment of economic uncertainty, business leaders and IP counsel need an understanding of business transactions and the role IP plays in those transactions; the changing global landscape; and anticipated regulatory challenges. During this session, our speakers will discuss the following:
Moderated by:
Antoinette F. Konski, Partner, Foley & Lardner LLP
Speakers:
Elin Hartrum, Director, Intellectual Property, Gilead Sciences, Inc.
Govind Gupta, Principal, Valuation & Business Modeling, Ernst & Young
Carol Cherkis, Ph.D., Life Sciences Consultant, NewCap Partners, Inc.
During the past several years, business development activity has a renewed focus on licensing and collaborations designed to continue to drive innovation, provide capital and further product portfolios. Throughout the past years, these types of transactions have progressed and new models for deal structures have been developed in response to factors including financial and regulatory challenges. There are benefits and disadvantages to deals as well as strategies for managing these complex strategic partnerships. During this session panelists will review the following:
Moderated by:
Richard Kaufman , Partner, Foley & Lardner LLP
Speakers:
Linda Pullan, Pullan Consulting
Roy Wu, Senior Vice President for Business Development, NovaBay Pharmaceuticals
Remi Brouard, Vice President, External Innovation, Sanofi-Aventis
Ethan K. Knowlden, Vice President, Business Development & Licensing, Corporate Counsel, Novartis Diagnostics
8:00 a.m. to 8:30 a.m. -
Registration
8:30 a.m. to 3:45 p.m. -
Program
11:40 a.m. to 1:15 p.m. -
Lunch